P1A-specific T-cell receptor (P1A-TCR)

The P1A-specific T-cell receptor (TCR) is a specialized immune receptor that recognizes the P1A tumor-associated antigen, a well-characterized model in murine tumor immunology (Van den Eynde et al., 1991). P1A is a non-mutated antigen encoded by the Trap1 gene, which is expressed in various mouse tumors, such as the P815 mastocytoma, but is restricted to the testis in normal tissues, making it a classic example of a cancer-testis antigen (Lethe et al., 1992). The TCR specifically identifies the P1A-derived nonamer peptide LPYLGWLVF when presented by the MHC class I molecule H-2Ld (Brandle et al., 1994). In the context of biotechnology and immunotherapy research, this TCR is frequently cloned and expressed in T cells (TCR-T therapy) to study the efficacy and safety of adoptive cell transfer. This system serves as a critical preclinical model for evaluating T-cell memory, exhaustion, and the impact of the tumor microenvironment on immunotherapy, providing foundational insights for human therapies targeting analogous antigens like MAGE or NY-ESO-1. Key therapeutic challenges include potential off-tumor toxicity due to expression in immune-privileged sites and the risk of tumor resistance through antigen loss.

Other names

P1A-specific TCRTrap1-specific T-cell receptorP815-specific T-cell receptorLPYLGWLVF-specific TCR

The P1A-specific T-cell receptor binds to the P1A peptide (LPYLGWLVF) presented by the MHC class I molecule H-2Ld on the surface of tumor cells, triggering a signaling cascade through the CD3 complex that results in T-cell activation, proliferation, and the release of cytotoxic granules to induce apoptosis in the target cell.